Hemophilia News and Research RSS Feed - Hemophilia News and Research

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.
Finding may help advance experimental approach to improving public health

Finding may help advance experimental approach to improving public health

Scientists have discovered a new way to manipulate how cells function, a finding that might help advance an experimental approach to improving public health: DNA vaccines, which could be more efficient, less expensive and easier to store than traditional vaccines. [More]
Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

Bayer HealthCare today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for BAY 81-8973, a recombinant Factor VIII compound. Bayer is seeking FDA approval of the investigational compound, proposed trade name Kovaltry, for the treatment of hemophilia A in children and adults. [More]
TSRI researchers show how ABC transporters cause multidrug resistance

TSRI researchers show how ABC transporters cause multidrug resistance

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy treatment. [More]
CSL Behring donates protein therapies to World Federation of Hemophilia

CSL Behring donates protein therapies to World Federation of Hemophilia

In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced today that it is donating 2 million international units (IUs) of protein therapies to the World Federation of Hemophilia. [More]
TSRI scientists show how to target weak spots of Marburg virus with future treatments

TSRI scientists show how to target weak spots of Marburg virus with future treatments

Marburg virus is Ebola's deadly cousin. The virus is up to 90 percent lethal—and doctors are desperate for tools to fight it. [More]
TSRI scientists develop new drug candidate against HIV

TSRI scientists develop new drug candidate against HIV

In a remarkable new advance against the virus that causes AIDS, scientists from the Jupiter, Florida campus of The Scripps Research Institute have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine. [More]
Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Scientists at The Scripps Research Institute have found diverse genomic changes in single neurons from the brains of Alzheimer's patients, pointing to an unexpected factor that may underpin the most common form of the disease. [More]
FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active. [More]
New study helps explain how booster shots trigger immune 'memory' to improve

New study helps explain how booster shots trigger immune 'memory' to improve

The last time you were in the doctor's office for a vaccine booster shot, did you wonder why you needed one? Exactly how booster shots offer long-term protection from viruses has long been a mystery to scientists. [More]
TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

A team at The Scripps Research Institute has won a $1,784,000 grant from the California Institute for Regenerative Medicine (CIRM). The funding will support the development of a new method for detecting DNA damage in stem cells to ensure that only the highest quality cells are used in transplantation or therapy. [More]
TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers. [More]
Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children? [More]
TSRI scientists awarded $2.3 million grant to find ways to erase traumatic memories

TSRI scientists awarded $2.3 million grant to find ways to erase traumatic memories

Scientists from the Florida campus of The Scripps Research Institute have been awarded $2.3 million from the Department of Health and Human Services of the National Institutes of Health to better understand how memories are stored in the hopes of eventually being able to treat posttraumatic stress disorder (PTSD) by erasing traumatic memories without altering other, more benign ones. [More]
Novo Nordisk introduces new initiative to support healthy lifestyle programming in New Jersey area

Novo Nordisk introduces new initiative to support healthy lifestyle programming in New Jersey area

Novo Nordisk today announced the launch of the Community Health Collaborative, a new initiative to support and expand healthy lifestyle programming in the Trenton, New Jersey area. [More]
Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B. [More]
Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment. [More]
BRI signs license agreement with SOBI for Kineret (anakinra)

BRI signs license agreement with SOBI for Kineret (anakinra)

Baylor Research Institute, the research arm of the Baylor Scott & White Health, announced that it has signed an agreement with Swedish Orphan Biovitrum AB (Sobi) to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SJIA or SOJIA) using interleukin-1 (IL-1) beta antagonists. [More]
Advertisement